Ken Griffin Morpho Sys Ag Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$17.36 - $19.34 $159,712 - $177,928	-9,200 Reduced 52.57%	8,300 $151,000
Q1 2024 May 15, 2024	SELL	$8.6 - $18.18 $38,700 - $81,810	-4,500 Reduced 20.45%	17,500 $317,000
Q4 2023 Feb 14, 2024	BUY	$4.55 - $9.9 $83,265 - $181,170	18,300 Added 494.59%	22,000 $217,000
Q3 2023 Nov 14, 2023	BUY	$6.72 - $8.6 $3,360 - $4,300	500 Added 15.63%	3,700 $24,000
Q2 2023 Aug 14, 2023	BUY	$3.95 - $7.74 $12,640 - $24,768	3,200 New	3,200 $23,000

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.